Foundayo Results: Weight Loss Timeline and Trial Data

The best Phase 3 evidence shows average weight loss of 12.4% after 72 weeks at the highest Foundayo-equivalent dose.

In ATTAIN-1, adults living with obesity or overweight and at least one weight-related health condition were given different doses of orforglipron or placebo alongside advice on diet and physical activity.

At week 72, average weight loss was:

The clinical trials used an earlier capsule formulation.

UK product information confirms that the 5.5mg, 9mg and 17.2mg Foundayo tablets provide equivalent exposure to the 6mg, 12mg and 36mg capsules respectively.

The results also show a clear dose-response relationship, with greater average weight loss at the higher doses.

Further reading: Foundayo dosage guide

To put the trial results into context, the table below shows what 11.2% and 12.4% weight loss would represent at different starting weights.

These are illustrations based on the average percentages reported in the trial. They are not predictions of individual weight loss.

Some people will lose substantially more than average, while others will lose less.

You may see slightly different figures for how much weight people lost with Foundayo in the ATTAIN-1 trial.

Both 11.2% and 12.4% are correct. They simply come from two different ways of analysing the study results.

12.4% average weight loss

People taking the highest dose lost an average of 12.4% of their starting weight after 72 weeks when researchers looked at the effect of treatment under the trial’s intended treatment conditions.

11.2% average weight loss

When researchers also took into account factors such as people stopping treatment or not remaining on their assigned treatment, average weight loss was approximately 11.2% after 72 weeks.

What does this mean for you?

A simple way to interpret the results is that the highest Foundayo dose produced around 11-12% average weight loss over 72 weeks.

For someone starting at 100kg, that would be approximately 11-12kg of weight loss on average.

These are averages from a clinical trial, so individual results can be higher or lower.

The ATTAIN-1 results also tell us how many participants reached clinically meaningful weight-loss targets.

Results after 72 weeks:

These figures come from the efficacy analysis of ATTAIN-1.

This means that at the highest dose, approximately:

• 3 in 4 people lost at least 5%
• 3 in 5 lost at least 10%
• 2 in 5 lost at least 15%
• 1 in 5 lost at least 20%

However, these were clinical-trial results and individual outcomes in routine treatment can be different.

Foundayo weight loss happens gradually.

There is not a reliable published average percentage for every individual month, so it is better to use actual clinical-trial measurement points rather than estimating how much someone should lose after one, two or three months.

The Phase 2 and Phase 3 studies used different study designs, doses and populations, so the figures should not be treated as a single continuous weight-loss curve.

Foundayo results after 1 month

There is currently no reliable clinical-trial figure showing the average amount of weight people lose after exactly one month on Foundayo.

Foundayo treatment begins at 0.8mg once daily and the dose is increased gradually.

The starting dose is primarily intended to introduce the medicine and help improve tolerability rather than to produce the maximum treatment effect immediately.

t is therefore too early to assess someone’s long-term response after only four weeks.

Foundayo results after 2 months

There is also no robust published average showing exactly how much weight patients should lose after two months.

By this point, a patient who has tolerated treatment may have moved from the starting dose to the next stage of treatment.

Some people may notice changes to appetite and weight during this period, while others may have a slower response.

This does not necessarily predict the eventual response to treatment.

Foundayo results after 3 months

After 3 months, weight loss may become clearer for some people. Appetite suppression may be more consistent, and changes in eating habits may become easier to maintain.

There is no exact 3-month average result from the main obesity trials, but clinical data shows that meaningful weight loss continues to build over the first 6 to 9 months of treatment.

Foundayo results after 6 months

Six months is a more useful point for assessing early Foundayo results.

In the Phase 2 obesity trial, average weight loss at 26 weeks ranged from 8.6% to 12.6%, depending on the dose used. Placebo weight loss was around 2.0% at the same time point.

This suggests that people who respond well to treatment may see meaningful weight loss by around 6 months.

Foundayo results after 9 months

At 36 weeks in the Phase 2 study, average weight loss ranged from 9.4% to 14.7% depending on dose.

Weight loss had not appeared to plateau by the end of the 36-week study.

Again, the Phase 2 study was different from the later Phase 3 programme, so these numbers should not be directly substituted for expected results with the licensed Foundayo dosing schedule.

Foundayo results after 1 year

There is no single published ATTAIN-1 headline figure at exactly 52 weeks that is as robust for patient counselling as the study’s final 72-week endpoint.

The strongest Phase 3 result therefore remains at 12.4% average weight loss after 72 weeks at the highest dose in the efficacy analysis.

It is better to use this established endpoint rather than estimate an average one-year percentage.

Foundayo results after 72 weeks

The most important Foundayo weight-loss data comes from the ATTAIN-1 Phase 3 trial at 72 weeks.

Participants taking the highest trial dose lost 12.4% of their starting body weight on average in the efficacy analysis.

The treatment-regimen analysis produced average weight loss of approximately 11.2%.

For someone weighing 100kg at the start of treatment, these averages would represent approximately 11.2kg to 12.4kg of weight loss.

Foundayo may start affecting appetite within the first few weeks, but visible weight loss usually takes longer.

Most people should think of Foundayo as a gradual treatment rather than a quick result. The first few months are mainly about starting treatment, increasing the dose and checking tolerability. More meaningful results are usually assessed after several months.

You may have seen figures suggesting weight loss of up to 14.7% after 36 weeks, which appears higher than the 12.4% reported after 72 weeks in ATTAIN-1.

This does not mean Foundayo became less effective in the longer Phase 3 trial.

The figures came from different studies.

The Phase 2 trial:

• included substantially fewer participants
• tested different investigational doses
• included a 45mg capsule dose that was not taken forward as the highest licensed tablet dose
• used a different study design
• used different statistical assumptions

ATTAIN-1 was a much larger Phase 3 study involving more than 3,100 participants and provides better evidence for estimating the expected effect of the dosing ultimately used to support licensing.

For this reason, the 72-week Phase 3 results should be given greater prominence when discussing expected Foundayo weight loss.

Foundayo has also been studied as a possible maintenance treatment after people have lost weight with injectable GLP-1 or GIP/GLP-1 medicines.

In the ATTAIN-MAINTAIN trial, people who switched to Foundayo maintained more of their previous weight loss than people switched to placebo.

This suggests Foundayo may have a future role in long-term weight management, although treatment decisions should always be made by a healthcare professional.

Take it consistently

Orforglipron is taken once daily. Missing doses regularly may reduce how well it works, especially for appetite control.

Follow the dosing schedule

GLP-1 medicines are usually increased gradually to improve tolerability and reduce side effects. Do not rush dose increases unless advised by your prescriber.

Prioritise protein

Eating enough protein can help preserve muscle while losing weight. This is especially important if your appetite is much lower than usual.

Reduce high-fat and heavy meals

Greasy, rich or very large meals can make GLP-1 side effects worse, especially nausea, reflux, bloating and diarrhoea.

Stay hydrated

Reduced appetite can sometimes mean you eat and drink less without realising. Aim to drink regularly throughout the day.

Strength train where possible

Resistance training helps protect muscle mass during weight loss and can improve body composition.

Build long-term habits

The best results come when orforglipron is combined with sustainable habits. If you stop treatment and return to previous eating patterns, weight regain is possible.

Foundayo results are promising, particularly because it is a tablet-based GLP-1 treatment.

In clinical trials, people taking the highest dose lost around 11.1% to 12.4% of their starting body weight over 72 weeks. Earlier Phase 2 data showed weight loss of 9.4% to 14.7% after 36 weeks, depending on dose.

Weight loss with Foundayo usually happens gradually. Some people may notice appetite changes within the first few weeks, but the most meaningful results are usually seen after several months.

Longer-term data is still needed to understand how well Foundayo results are maintained beyond 72 weeks.